Evidence map›Paper›PMID 11973645›Full record

ArticleOncogene2002

Regulation of aromatase promoter activity in human breast tissue by nuclear receptors.

Chun Yang, Bin Yu, Dujin Zhou, Shiuan Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  7. Article
  8. Regulation of aromatase induction by nuclear receptor coregulator PELP1.The Journal of steroid biochemistry and molecular biology · 2010
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chun YangBeckman Research Institute of the City of Hope, Division of Immunology, 1450 East Duarte Road, Duarte, California, CA 91010-0269, USA.
Bin Yu
Dujin Zhou
Shiuan Chen
Beckman Research InstituteCity of Hope · US

Funding

AROMATASE AND BREAST CANCERR01CA044735 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI CHEN, SHIUAN · 1988 to 2009
$4.0M
ENDOCRINE DISRUPTING CHEMICALS AND AROMATASER01ES008258 · NIEHS · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI CHEN, SHIUAN · 1996 to 2009
$2.6M
NCI NIH HHS CA44735NCI NIH HHS CA65767NIEHS NIH HHS ES08258
6 · The paper itself

Abstract

Using the yeast one-hybrid approach to screen a human breast tissue hybrid cDNA expression library, we have found that four orphan/nuclear receptors, ERRalpha-1, EAR-2, COUP-TFI (EAR-3), and RARgamma, bind to the silencer (S1) region of the human aromatase gene. S1 down regulates promoters I.3 and II of the human aromatase gene. In this study, the interaction of EAR-2, COUP-TFI, and RARgamma with S1 was confirmed by DNA mobility shift analysis. In contrast to the findings that ERRalpha-1 behaves as a positive regulatory factor, these three nuclear receptors were found, by mammalian cell transfection experiments, to act as negative regulatory factors by binding to S1. Furthermore, the negative action of these three nuclear receptors could override the positive effect of ERRalpha-1. RT-PCR analysis of 11 cell lines and 55 human breast tumor specimens has shown that these nuclear receptors are expressed in human breast tissue. Since EAR-2, COUP-TFI, and RARgamma are expressed at high levels, it is likely that S1 is a negative regulatory element that suppresses aromatase promoters I.3 and II in normal breast tissue. In cancer tissue, S1 may function as a positive element since ERRalpha-1 is expressed, but EAR-2 and RARgamma are only present in a small number of tumor specimens. This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue. Our studies have revealed that estrogen receptor alpha (ERalpha) can also bind to S1, in a ligand-dependent manner. By binding to S1, ERalpha down-regulates the aromatase promoter activity. These results demonstrate that nuclear receptors play important roles in modulating aromatase expression in human breast tissue.

Indexed as

Promoter Regions, GeneticAromataseBreastBreast NeoplasmsCOUP Transcription Factor IDNA-Binding ProteinsElectrophoretic Mobility Shift AssayERRalpha Estrogen-Related ReceptorFemaleHumansReceptors, Cytoplasmic and NuclearReceptors, EstrogenReceptors, GlucocorticoidReceptors, Retinoic AcidReceptors, SteroidRepressor ProteinsAromataseCOUP Transcription Factor IDNA-Binding ProteinsERRalpha Estrogen-Related ReceptorNR2F1 protein, humanNR2F6 protein, humanReceptors, Cytoplasmic and NuclearReceptors, EstrogenReceptors, GlucocorticoidReceptors, Retinoic AcidReceptors, SteroidRepressor ProteinsRetinoic Acid Receptor gammaTranscription Factors

Identifiers

PMID11973645
OpenAlexW1983954145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.